Table 6 Segmented regression analysis of relative risk (RR) for measles-containing vaccine coverage (MCV1 and MCV2), measles cases, and mortality rates pre- and post-COVID-19 pandemic
From: Attention to COVID 19 pandemic resulted in increased measles cases and deaths in Zambia
Type of vaccine | Mean monthly count | Mean monthly rate per 100,000 | Slope change Pre-COVID-19 | p value | Slope change during-COVID-19 | p value | Step change | p value | ||
|---|---|---|---|---|---|---|---|---|---|---|
Before COVID-19 | After COVID-19 | Before COVID-19 | After COVID-19 | RR (95% CI)a | RR (95%CI)C | RR (95%CI)c | ||||
Measles cases | 78.1 | 387.6 | 0.02 | 0.11 | 0.99 (0.97–1.01) | 0.398 | 1.04 (1.01–1.06) | 0.004 | 0.67 (0.31–1.45) | 0.3034 |
Measles mortality | 1.9 | 8.7 | 0.1 | 0.22 | 0.99 (0.98–1.01) | 0.558 | 1.02 (1.00–1.03) | 0.028 | 1.81 (1.14–2.87) | 0.011 |
Measles dose 1 | 53,465 | 56,493 | 1643 | 1575 | 0.998 (0.994–1.001) | 0.063 | 1.00 (0.99–1.01) | 0.240 | 0.91 (0.78–1.07) | 0.271 |
Measles dose 2 | 52,820 | 40,418 | 1628 | 1126.4 | 0.998 (0.996–1.000) | 0.063 | 1.003 (1000–1.010) | 0.042 | 0.58 (0.46–0.72) | 0.0001 |